Patanjali Ayurved Ltd. informed the Supreme Court on Tuesday that it has halted the sale of 14 products whose manufacturing licenses were suspended by the Uttarakhand State Licensing Authority in April.
The company stated before a bench of Justices Hima Kohli and Sandeep Mehta that it has instructed 5,606 franchise stores to withdraw these products.
Additionally, it has directed media platforms to cease advertising these 14 products.
The bench directed Patanjali to file an affidavit within two weeks confirming whether social media intermediaries have complied with the request to remove advertisements and whether all advertisements of the 14 products have been withdrawn. The matter is scheduled for further hearing on July 30.
The Supreme Court is hearing a plea by the Indian Medical Association (IMA) alleging a smear campaign by Patanjali against the COVID-19 vaccination drive and modern medicine. The Uttarakhand State Licensing Authority had previously informed the court that the manufacturing licenses for the 14 products of Patanjali Ayurved Ltd and Divya Pharmacy were “suspended with immediate effect.”
On May 14, the Supreme Court reserved its order on the contempt notice issued to yoga guru Ramdev, his aide Balkrishna, and Patanjali Ayurved Ltd concerning misleading advertisements.
